

Abgeschlossene PhD-/ MD-Projekte

Name	Title	Period
• Vlad Moisoiu	Temozolomide-Induced mismatch repair deficiency accelerates tumor growth and induces radiosensitivity in gliomas	02/2021 – 07/2024
• Maximilian Mastall	VEGFR2-targeting CAR T cells in syngeneic and xenograft mouse glioma models	01/2021 – 07/2024
• Flavio Vasella	CRISPR/Cas-mediated base editing to correct recurrent point mutations in tumors of the central nervous system	04/2018 – 10/2023
• Remi Weber	CRISPR/Cas9 precision base editing and epigenetic engineering in glioma	03/2020 – 10/2023
• Gioele Medici	The intra-tumoral spatial heterogeneity of T cell antigens in glioblastoma: an integrated multi-omics approach	11/2019 – 10/2023
• Thomas Look	Advancing immunotherapy for glioblastoma with immunocytokines	03/2020 – 10/2023
• Roxanne Lourman	Oncogenic roles of MSH6 loss in glioblastoma	12/2018 – 11/2022
• Marcel Bühler	Longitudinal Characterization of the Glioblastoma Proteome Using PCT-SWATH Mass Spectrometry	01/2019 – 10/2022
• Danielle Villars	Targeting α_v Integrins with CAR T Cells as a Novel Therapeutic Strategy against Gliomas	04/2019 – 10/2021
• Daniela Lorizio	Targeting glioblastoma by immune checkpoint modulation and TGF- β inhibition	01/2018 – 07/2021
• Clara Quijano Rubio	The role of CD95 and CD95L interactions in human glioma-initiating cells and in syngeneic mouse glioma models	12/2017 – 07/2021
• Evelina Blomberg	The role of type I IFN and PD-L1 in syngeneic mouse glioma models	12/2017 – 07/2021
• Lena Hänsch	Characterizing CD317 as a novel target for chimeric antigen receptor (CAR) T cell therapy in glioblastoma	05/2017 – 03/2021

Name	Title	Period
• Konstantina Kapolou	The antigenic landscape of glioblastoma: refining the targets for immunotherapy	09/2016 - 12/2019
• Tobias Weiss	Characterization and exploitation of the NKG2D system in glioblastoma	09/2015 – 04/2019
• Caroline von Achenbach	Growth factor signalling in glioblastoma	02/2015 – 09/2018
• Birthe Lohmann	Modulation of glioblastoma biology by type I interferons	01/2015 – 09/2018
• Elisa Ventura	Extracellular control of TGF-beta signaling in glioblastoma	01/2013 – 06/2017
• Eleanna Papa	Crosstalk between the Met and TGF- β pathways in glioblastoma	01/2013 – 06/2017
• Davide Mangani	Co-inhibition of the TGF- β and VEGF pathways in glioblastoma	01/2013 – 06/2017
• Alexandros Papachristodoulou	Focused ultrasound-mediated delivery of encapsulated MGMT antagonists for the treatment of temozolomide-resistant glioblastoma	01/2013 – 05/2017
• Krishnan Shanmugarajan	Modulation of cerebral endothelial cell function by glioma-derived factors	10/2012 – 04/2016
• Judith Schroeder	The role of TGF- β coreceptors in glioblastoma	10/2012 – 09/2015
• Nina Stojceva	TMZ resistance in glioblastoma	01/2012 – 06/2015
• Paula Codo	Growth and differentiation factor (GDF)-15, microRNA and the immunophenotype of glioblastoma	02/2011 – 09/2014
• Mushfika Ahmad	How stem-like are sphere cultures from long-term cancer cell lines?	08/2010 – 11/2013
• Manuela Silginer	Integrin inhibition interferes with TGF-beta signaling in malignant glioma cells	01/2010 – 10/2013